Share price of Cipla gained 2.5 percent in the early trade on Monday after USFDA issued zero observations for its Indore facility.
United States Food and Drug Administration (USFDA) conducted a post-approval inspection at company's Indore facility from May 13 to May 17, 2019 and the said inspection ended with zero observations.
At 09:42 hrs Cipla was quoting at Rs 555.10, up Rs 11.15, or 2.05 percent on the BSE.
The share touched its 52-week high Rs 678 and 52-week low Rs 483.75 on 19 September, 2018 and 29 January, 2019, respectively.
If you want to know more about our services, please visit Share Market Tips
No comments:
Post a Comment